ORIC - Oric Pharmaceuticals, Inc.
IEX Last Trade
8.26
-0.120 -1.453%
Share volume: 6,481
Last Updated: Thu 26 Dec 2024 08:30:17 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$8.38
-0.12
-1.43%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.68%
1 Month
-16.43%
3 Months
-20.95%
6 Months
23.53%
1 Year
-10.59%
2 Year
50.28%
Key data
Stock price
$8.26
DAY RANGE
$8.10 - $8.40
52 WEEK RANGE
$6.71 - $16.65
52 WEEK CHANGE
-$10.98
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Jacob M. Chacko
Region: US
Website: oricpharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: oricpharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
ORIC Pharmaceuticals, Inc. discovers and develops therapies for treatment of cancers. Its product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Recent news